PMID- 37718409
OWN - NLM
STAT- MEDLINE
DCOM- 20230919
LR  - 20231122
IS  - 1528-3658 (Electronic)
IS  - 1076-1551 (Print)
IS  - 1076-1551 (Linking)
VI  - 29
IP  - 1
DP  - 2023 Sep 18
TI  - Regulation of sexually dimorphic placental adaptation in LPS exposure-induced 
      intrauterine growth restriction.
PG  - 114
LID - 10.1186/s10020-023-00688-5 [doi]
LID - 114
AB  - BACKGROUND: Sexual dimorphism in placental physiology affects the functionality 
      of placental adaptation during adverse pregnancy. Defects of placental function 
      compromise fetal programming, affecting the offspring's adult life. However, 
      studies focusing on the relationship between sex-specific placental adaptation 
      and consequent fetal maldevelopment under sub-optimal uterus milieu are still 
      elusive. METHODS: Here, we investigated the effects of maternal 
      lipopolysaccharide (LPS) exposure between placental sex. Pregnant ICR mice 
      received intraperitoneal injection of phosphate-buffered saline or 100, 200, and 
      400 microg/kg LPS on the gestational day (GD) 15.5. To determine whether prenatal 
      maternal LPS exposure resulted in complicated pregnancy outcomes, survival rate 
      of embryos was calculated and the growth of embryos and placentas was examined. 
      To elucidate global transcriptomic changes occurring in the placenta, total 
      RNA-sequencing (RNA-seq) was performed in female and male placentas. RESULTS: LPS 
      administration induced placental inflammation in both sexes at GD 17.5. Prenatal 
      infection resulted in growth retardation in both sexes of embryos, and especially 
      more prevalently in male. Impaired placental development was observed in a 
      sex-specific manner. LPS 400 microg/kg reduced the percentage area of the labyrinth 
      in females and junctional zone in males, respectively. RNA-sequencing revealed 
      widespread sexually dimorphic transcriptional changes in placenta. In particular, 
      representative changes were involved in biological processes such as trophoblast 
      differentiation, nutrient/ion transporter, pregnancy, and immune system. 
      CONCLUSIONS: Our results present the sexually dimorphic responses of placental 
      physiology in intrauterine growth restriction model and provide tentative 
      relationship further to be elucidated between sex-biased placental functional 
      change and long-term effects on the offspring's later life.
CI  - (c) 2023. The Feinstein Institute for Medical Research.
FAU - Jeong, Da Som
AU  - Jeong DS
AD  - Department of Anatomy, Embryology Laboratory, Yonsei University College of 
      Medicine, Seoul, 03722, Republic of Korea.
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      03722, Republic of Korea.
FAU - Lee, Ji-Yeon
AU  - Lee JY
AD  - Vivozon, Inc, Kolon Digital Tower3, 49, Achasan-ro, Seongdong-gu, Seoul, Republic 
      of Korea.
FAU - Kim, Myoung Hee
AU  - Kim MH
AD  - Department of Anatomy, Embryology Laboratory, Yonsei University College of 
      Medicine, Seoul, 03722, Republic of Korea. mhkim1@yuhs.ac.
FAU - Oh, Ji Hoon
AU  - Oh JH
AUID- ORCID: 0000-0001-5652-1452
AD  - Department of Biological Sciences, Keimyung University College of Natural 
      Sciences, Daegu, 42601, Republic of Korea. dr.jihoonoh@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230918
PL  - England
TA  - Mol Med
JT  - Molecular medicine (Cambridge, Mass.)
JID - 9501023
RN  - 0 (Lipopolysaccharides)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Female
MH  - Male
MH  - Pregnancy
MH  - Mice
MH  - Animals
MH  - Humans
MH  - Mice, Inbred ICR
MH  - *Fetal Growth Retardation/chemically induced
MH  - *Lipopolysaccharides
MH  - Placenta
MH  - RNA
PMC - PMC10506314
OTO - NOTNLM
OT  - Intrauterine growth restriction
OT  - Placenta transcriptome
OT  - Placental adaptation
OT  - Prenatal maternal stress
OT  - Sexual dimorphism
COIS- Author Ji-Yeon Lee is employed by Vivizon Co. The remaining authors declare that 
      the research was conducted without any commercial or financial relationships that 
      could be construed as a potential conflict of interest.
EDAT- 2023/09/18 00:41
MHDA- 2023/09/19 06:42
PMCR- 2023/09/18
CRDT- 2023/09/17 23:13
PHST- 2022/11/20 00:00 [received]
PHST- 2023/06/15 00:00 [accepted]
PHST- 2023/09/19 06:42 [medline]
PHST- 2023/09/18 00:41 [pubmed]
PHST- 2023/09/17 23:13 [entrez]
PHST- 2023/09/18 00:00 [pmc-release]
AID - 10.1186/s10020-023-00688-5 [pii]
AID - 688 [pii]
AID - 10.1186/s10020-023-00688-5 [doi]
PST - epublish
SO  - Mol Med. 2023 Sep 18;29(1):114. doi: 10.1186/s10020-023-00688-5.